



Attorney Docket No. 701586-53303

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Charles R. Cantor et al.

Application No.: 10/529,122 Group No.: To be assigned
Filed: October 9, 2003 (IA DATE) Examiner: To be assigned
Confirmation No.: 1567 Customer No.: 50607
Title: NUCLEIC ACID SUPPORTED PROTEIN COMPLEMENTATION

MAIL STOP AMENDMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is, on the date shown below, being: deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Date: September 15, 2005


Linda M. Ginsberg

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached forms PTO/SB/08 a and b, for consideration by the Examiner in connection with the examination of the above-identified patent application.

I. REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- (2) within three months of the mailing date of the PCT International Search Report;
- or

In re application of: Charles R. Cantor et al.

Application No.:	10/529,122	Group No.:	To be assigned
Filed:	October 9, 2003 (IA DATE)	Examiner:	To be assigned
Confirmation No.:	1567	Customer No.:	50607
Title:	NUCLEIC ACID SUPPORTED PROTEIN COMPLEMENTATION		

- (3) after the period defined in (1) but before the mailing date of a **Final Rejection** or **Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or
- (4) after the mailing date of a **Final Rejection** or **Notice of Allowance** but before the payment of the **Issue Fee**, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached form(s) PTO/SB/08a and b be made of record in this application. Copies of these documents (CHECK ONE):


- X are enclosed herewith; and
- have been cited in the parent application, and are thus not being resubmitted herein.

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,



Ronald I. Eisenstein (Reg. No. 30,628)
Nicole L.M. Valtz (Reg. No. 47,150)
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110
(617) 345-6057

Date: September 15, 2005



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/529,122
				I.A. Filing Date	October 9, 2003
				First Named Inventor	Charles R. Cantor
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	3	Attorney Docket Number	701586-53303

U.S. PATENT DOCUMENTS					
Examiner Initials ⁵	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US-2002/0064779	05/30/2002	Landegren et al.	
	A2	US-2003/0049688	03/13/2003	Michnick et al.	
	A3	US-6,270,964	08/07/2001	Michnick et al.	
	A4	US-6,294,330	09/25/2001	Michnick et al.	
	A5	US-6,428,951	08/06/2002	Michnick et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ⁵	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ² (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/529,122	
			Filing Date	October 9, 2003	
			First Named Inventor	Charles R. Cantor	
			Group Art Unit	To be assigned	
Examiner Name	To be assigned				
Sheet	2		3	Attorney Docket Number	701586-53303

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	BEACH, Dale L. et al.; Current Biology; 9(11):569-578 (1999)	
	C2	BERTRAND, Edouard et al.; Molecular Cell; 2:437-445 (10/1998)	
	C3	BIRKENMEYER, Larry G. et al.; Journal of Virological Methods; 35:117-126 (1991)	
	C4	CARMO-FONSECA, Maria et al.; Critical Reviews in Eukaryotic Gene Expression; 9(3&4):213-219 (1999)	
	C5	LANDEGREN, Ulf; Trends Genetics; 9(6):199-204 (1993)	
	C6	MATSUO, Toshihiko; Biochimica et Biophysica ACTA; 1379:178-184 (1998)	
	C7	MOLENAAR, C. et al.; Nucleic Acids Research; 29(17):E89:1-9 (2001)	
	C8	OLEYNIKOV, Yuri et al.; Current Biology; 13:199-207 (02/04/2003)	
	C9	PEDERSON, Thoru; Nucleic Acids Research; 29(5):1013-1016 (2001)	
	C10	PELLETIER, Joelle N. et al.; Proc. Natl. Acad. Sci. USA; 95:12141-12146 (10/1998)	
	C11	PERLETTE, John et al.; Anal. Chem.; 73:5544-5550 (2001)	
	C12	ZUBRITSKY, Elizabeth; Anal. Chem.; 73:657A (2001)	
	C13	POLITZ, Joan C.; Trends in Cell Biology; 9:284-287 (07/1999)	
	C14	SANDO, Shinsuke et al.; J. Am. Chem. Soc.; 124(33):9686-9687 (2002)	

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known			
				Application Number		10/529,122	
				Filing Date		October 9, 2003	
				First Named Inventor		Charles R. Cantor	
				Group Art Unit		To be assigned	
Examiner Name		To be assigned					
Sheet	3		3	Attorney Docket Number		701586-53303	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C15	SEI-IIDA, Yukari et al.; Nucleic Acids Research; 28(12):e59:i-vii (2000)	
	C16	SOKOL, Deborah L. et al.; Proc. Natl. Acad. Sci. USA; 95:11538-11543 (09/1998)	
	C17	ST. JOHNSON, Daniel; Cell; 81:161-170 (04/21/1995)	
	C18	TSUJI, Akihiko et al.; Biophysical Journal; 81:501-515 (07/2001)	
	C19	TSUJI, Akihiko et al.; Biophysical Journal; 78:3260-3274 (06/2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.